Euro
USD
British Pound
NULL
Product Description
The research-grade biosimilar is an investigational human monoclonal antibody that targets angiopoietin-like 3 inhibitor (ANGPTL3). ANGPTL3 is primarily expressed in the liver and it inhibits LPL activity and endothelial lipase activity. This prevents the clearance of lipids and raises the concentration of triglycerides and LDL-C in the blood. The antibody binds with high affinity and specificity to ANGPTL3 and reverses the inhibitory action on LPL, thus promoting the clearance of LDL-C from the blood. The original drug was awarded breakthrough therapy designation by the FDA to treat patients suffering from homozygous familial hypercholesterolemia (HoFH).
Biovision | A2171 | Anti-ANGPTL3 (Evinacumab), Human IgG4 Antibody DataSheet
Antibody Target: ANGPTL3
Target Alternative Name: REGN 1500, REGN1500, ANL3, ANG-5, FHBL2, ANGPT5
Tag Line: The biosimilar is a human monoclonal antibody that targets ANGPTL3 and reverses its inhibitory activity on LPL. This results in increased clearance of LDL-C from the blood
Category: Biosimilars
Host: Recombinant
Isotype: IgG4, kappa
Species Reactivities: Human
Immunogen Sequence: Human ANGPTL3
Accession #: DB15354
Gene ID:
Appearance: Colorless liquid
Form: Liquid
Concentration: 1 mg/ml
Formulation: In PBS, pH 7.5
Purification: Protein A purified
Application:
Positive Control:
Application And Usages:
Country of Animal Origin: USA
Country of Manufacture: USA
Usage: For Research Use Only! Not to be used in humans.
Handling: The antibody solution should be gently mixed before use.
Western Blot Verified: FALSE
Immunocytochemistry Verified: FALSE
Immunofluorescence Verified: FALSE
Immunoprecipitation Verified: FALSE
FACS Verified: FALSE
ELISA Verified: FALSE
ChIP Verified: FALSE
Dot Blot Verified: FALSE
Flow Cytometry Verified: FALSE
